Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

Description

The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. The goal is to see if this imaging technique can help differentiate infections from non-infectious processes and also provide information on the causative bacterial class.

Conditions

Renal Excretion, Bacterial Infections, Inflammatory Disease, Oncologic Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. The goal is to see if this imaging technique can help differentiate infections from non-infectious processes and also provide information on the causative bacterial class.

Phase 1 Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid (11C-PABA)

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

Condition
Renal Excretion
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins Medical Institutions, Baltimore, Maryland, United States, 21218

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female ≥18 years of age at the time of consent and imaging.
  • 2. Healthy subjects OR those with confirmed (microbiologically, molecular or serological testing) diagnosis of infection at any body site OR clinical and imaging evidence of suspected infection in any body site with confirmation (microbiologically, molecular or serological testing) anticipated within 72 hours of imaging.
  • 3. For subjects with infections:
  • 4. For inpatients, determined by the attending of record to be stable to participate in the study (will be documented in the research records).
  • 5. Subject is judged by the investigator to have the initiative and means to be compliant with the protocol.
  • 6. Subjects or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. Adults lacking capacity will not be enrolled in this study.
  • 1. Reported pregnancy or pregnancy as determined by positive or indeterminate serum human chorionic gonadotrophin (hCG) at screening and positive urine hCG prior to radiopharmaceutical dosing.
  • 2. Lactating females.
  • 3. Inadequate venous access.
  • 4. Screening clinical laboratory values must be within normal limits or judged not clinically significant by the principal investigator.
  • 5. Administered a radioisotope within 5 physical half-lives prior to study enrollment.
  • 6. Subject has been treated with an investigational drug / biologic / therapeutic device within 30 days prior to study radiotracer administration.
  • 7. Determined to have prior (external) radiation exposure which will exceed RDRC annual radiation exposure limit of 5 rems.
  • 8. For patients undergoing renal imaging they will be excluded if any of the following conditions exist:
  • * Hypertension
  • * Diabetes mellitus type I or II
  • * Body mass index less than 18.5 kg/m2 or higher than 30 kg/m2
  • * Family history of renal disease
  • * Urinary tract infection in the prior 6 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Sanjay K Jain, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2027-11-26